<DOC>
	<DOCNO>NCT01395745</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety subcutaneous blisibimod administer addition standard therapy subject active Systemic Lupus Erythematosus ( SLE ) disease define SELENA-SLEDAI score ≥10 despite on-going stable corticosteroid therapy .</brief_summary>
	<brief_title>CHABLIS-SC1 : A Study Efficacy Safety Subcutaneous Blisibimod Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Fulfill least 4 diagnostic criterion SLE define American College Rheumatology Positive antinuclear antibody ( ANA ) and/or antidouble strand DNA ( antidsDNA ) Active SLE disease define SELENASLEDAI score ≥10 despite ongoing stable corticosteroid therapy 18 year age old Severe active vasculitis , active central nervous system lupus , active lupus nephritis , uncontrolled hypertension poorly control diabetes Malignancy within past 5 year Known positive HIV and/or positive screen visit hepatitis B , hepatitis C Liver disease Anemia , neutropenia , thrombocytopenia Active infection require hospitalization treatment parenteral antibiotic within past 60 day history repeat herpetic viral infection History active tuberculosis history tuberculosis infection Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Lupus Erythematosus , Systemic</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>A-623</keyword>
	<keyword>Blisibimod</keyword>
</DOC>